Fig. 1.
Fig. 1. Schematic representation of membrane-bound factor Va/VaLeiden heavy-chain inactivation by APC. Normal plasma factor Va is inactivated following three ordered and sequential cleavages in the heavy chain at Arg506, Arg306, and Arg679.45 Cleavage at Arg506, which gives rise to an Mr = 75,000 fragment and an Mr = 28/26,000 doublet, is necessary to optimally expose the site at Arg306. Further cleavage at Arg306yields an Mr = 45,000 fragment and an Mr = 30,000 fragment.45 Individuals with the Arg506→ Gln mutation (factor VLeiden) no longer have a cleavage site at position 506, which slows the rate of cleavage at Arg306.46 Cleavage at Arg306 yields an Mr = 45,000 fragment and an Mr = 60/58,000 doublet. Further cleavage of the Mr = 60/58,000 doublet at Arg679 yields an Mr = 54,000 fragment. Fragments that are recognized by the monoclonal antibody (HFVaHC#17) used in this study are indicated by the shaded boxes.25

Schematic representation of membrane-bound factor Va/VaLeiden heavy-chain inactivation by APC. Normal plasma factor Va is inactivated following three ordered and sequential cleavages in the heavy chain at Arg506, Arg306, and Arg679.45 Cleavage at Arg506, which gives rise to an Mr = 75,000 fragment and an Mr = 28/26,000 doublet, is necessary to optimally expose the site at Arg306. Further cleavage at Arg306yields an Mr = 45,000 fragment and an Mr = 30,000 fragment.45 Individuals with the Arg506→ Gln mutation (factor VLeiden) no longer have a cleavage site at position 506, which slows the rate of cleavage at Arg306.46 Cleavage at Arg306 yields an Mr = 45,000 fragment and an Mr = 60/58,000 doublet. Further cleavage of the Mr = 60/58,000 doublet at Arg679 yields an Mr = 54,000 fragment. Fragments that are recognized by the monoclonal antibody (HFVaHC#17) used in this study are indicated by the shaded boxes.25 

Close Modal

or Create an Account

Close Modal
Close Modal